Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 21 of the 42 sources its claims cite were checked for support.
Abstract
Cellular senescence, a stress-induced irreversible growth arrest often characterized by expression of p16(Ink4a) (encoded by the Ink4a/Arf locus, also known as Cdkn2a) and a distinctive secretory phenotype, prevents the proliferation of preneoplastic cells and has beneficial roles in tissue remodelling during embryogenesis and wound healing. Senescent cells accumulate in various tissues and organs over time, and have been speculated to have a role in ageing. To explore the physiological relevance and consequences of naturally occurring senescent cells, here we use a previously established transgene, INK-ATTAC, to induce apoptosis in p16(Ink4a)-expressing cells of wild-type mice by injection of AP20187 twice a week starting at one year of age. We show that compared to vehicle alone, AP20187 treatment extended median lifespan in both male and female mice of two distinct genetic backgrounds. The clearance of p16(Ink4a)-positive cells delayed tumorigenesis and attenuated age-related deterioration of several organs without apparent side effects, including kidney, heart and fat, where clearance preserved the functionality of glomeruli, cardio-protective KATP channels and adipocytes, respectively. Thus, p16(Ink4a)-positive cells that accumulate during adulthood negatively influence lifespan and promote age-dependent changes in several organs, and their therapeutic removal may be an attractive approach to extend healthy lifespan.
Overview
CoChat Summary
TL;DR
Clearance of naturally occurring p16Ink4a-positive senescent cells in non-progeroid INK-ATTAC mice starting at 12 months of age extended median lifespan and delayed multiple age-related pathologies. The authors conclude that p16Ink4a-positive cells that accumulate during adulthood negatively influence lifespan and promote age-dependent changes in several organs.
Key findings
- AP20187 treatment extended median lifespan in both sexes and two genetic backgrounds: mixed-background mice by 27% and C57BL/6 mice by 24% when sexes were combined; sex-specific median lifespan increases ranged from 17% to 35%. Maximum lifespan was significantly increased only for mixed AP-treated males and females combined (p = 0.0295), not for C57BL/6 mice or individual sexes.
- Clearance delayed tumorigenesis and increased tumor latency without changing the incidence or spectrum of macroscopically detectable tumors at autopsy; median lifespan extension among AP-treated mice dying without tumors ranged from 24% to 42%.
- Clearance attenuated age-related deterioration in fat, kidney, heart, and eye: it prevented fat mass loss and adipogenesis marker declines, reduced glomerulosclerosis and blood urea nitrogen increases, reduced cardiomyocyte hypertrophy and preserved cardiac stress tolerance, and delayed cataract formation. It also prevented age-dependent reductions in spontaneous activity and exploratory behavior.
- Clearance was partial and tissue selective: p16Ink4a-positive cells were reduced in most tissues examined but not colon or liver. In iWAT, AP-treated mice had 8-fold fewer GFP+ adipocyte progenitors; X-Gal crystal-containing cells were 0.2% vs 1.6% in iWAT and 0.3% vs 1.2% in kidney for AP-treated vs untreated mice, respectively.
Methods
- Two consecutive cohorts of INK-ATTAC transgenic mice were injected twice weekly with AP20187 or vehicle beginning at 12 months of age until moribund or death. The first cohort was on a mixed 129Sv × C57BL/6J × FVB background fed a 9% fat diet; the second was on a congenic C57BL/6J background fed a 5% fat diet. Dosing was 0.2 μg AP20187/g body weight between 12 and 18 months and 2.0 μg/g thereafter in the mixed cohort, and 2.0 μg/g from 12 months in the C57BL/6J cohort.
- Lifespan was analyzed with survival curves and log-rank tests; maximum lifespan was tested with two-sided Wang-Allison tests. Healthspan analyses at 18 months included qRT-PCR for senescence and inflammation markers, FACS, SAβ-Gal staining, TEM with X-ray elemental analysis, echocardiography, cardiac stress tests, metabolic and behavioral assays, and histology.
- The paper states that no power calculations were used; sample sizes were based on previously published experiments where differences were observed. Investigators were blinded to allocation during experiments and outcome assessment except for rare instances where blinding was not possible.
Limitations
- The authors state that clearance was partial and several key tissues were refractory, including liver and colon; they note that further optimization of senescent cell removal protocols is needed.
- The authors state that repetitive vehicle injection stress may have negatively impacted longevity of male C57BL/6 mice, and that maximum lifespan was not extended in C57BL/6 AP-treated animals.
- The authors state that their limited analyses do not exclude the possibility that other p16Ink4a-positive non-senescent cells engage ATTAC and die upon AP exposure; they also note that no power calculations were used.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 5 Not valid · 8 Not checked · 114 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Earlier we have shown that, in BubR1 progeroid mice, ATTAC ablates p16 Ink4a -positive senescent cells upon administration of AP20187 (AP), a dimerizer that activates FKBP-fused Casp8 4 .”
What the sources say
- Supportedcites [4] 4. Baker DJ, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011; 479:232-236. [PubMed: 22048312] source
In the main text (Fig. 3a–e), AP20187-treated BubR1H/H;INK-ATTAC mice show reduced senescence markers, which the authors interpret as clearance of senescent cells. The Methods ('Mouse strains and drug treatments') identifies AP20187 as the dimer-inducing drug, and the main text describes activation of the FKBP–Casp8 fusion protein by AP20187. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ATTAC was also not induced in peripheral blood T lymphocytes that robustly engage endogenous p16 Ink4a with aging without concomitant expression of multiple senescence markers 2 , 13 (Extended Data Fig. 2h), further implying that transgene induction is quite selective for senescence.”
What the sources say
- Not checked — no full text of the sourcecites [2] 2. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015; 15:397408. [PubMed: 26105537] source
- Partly supportedcites [13] 13. Liu Y, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009; 8:439-448. [PubMed: 19485966] sourceExperimental — accuracy not yet measured
The section ‘Increased p16 INK4a expression is associated with chronological age’ reports that p16 INK4a expression in peripheral blood T lymphocytes increases with age (page unavailable). It does not address ATTAC induction or establish whether those cells express multiple senescence markers, so it supports only the aging-related p16 portion of the attributed claim. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“When AP was administered during wound closure, healing was delayed with similar kinetics as 4- or 18-month-old ATTAC mice without prior AP treatment, indicating that acute senescence mechanisms are preserved with aging and not influenced by constitutive clearance of senescent cells 3 .”
What the sources say
- Could not verifycites [3] 3. van Deursen JM. The role of senescent cells in ageing. Nature. 2014; 509:439-446. [PubMed: 24848057] sourceExperimental — accuracy not yet measured
The 'Senescence in ageing and age-related disease' section says AP20187 was used to eliminate senescent cells in INK-ATTAC mice. The 'Acute versus chronic senescence' section discusses senescence during wound closure, but neither section reports AP administration during wound closure, delayed healing, or a comparison with untreated 4- or 18-month-old mice. Pages were not provided in our copy. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with a beneficial role of senescent cells only for the duration of wound repair 6 - 8 , 18-month-old AP-treated ATTAC mice repaired cutaneous wounds when drug administration was suspended during healing (Extended Data Fig. 10ac).”
What the sources say
- Could not verifycites [6] 6. Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol. 2010; 12:676-685. [PubMed: 20526329] sourceExperimental — accuracy not yet measured
The Methods (Animals and cutaneous wound healing) describe 12-week-old Ccn1 mice, and the Results report wound healing in those mice. Our copy does not report 18-month-old ATTAC mice, AP treatment, or suspension of treatment during healing. In the citing sentence, this citation appears to support the preceding background point about senescent cells in wound repair; the ATTAC observation is presented as the citing authors’ own Extended Data result. (LLM, conf=0.78)
- Could not verifycites [7] 7. Krizhanovsky V, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134:657-667. [PubMed: 18724938] sourceExperimental — accuracy not yet measured
The Animals and Results sections describe mice studied for liver fibrosis, not AP-treated ATTAC mice or cutaneous wound repair. The Discussion suggests that senescence may be relevant to other wound-healing responses, but our copy does not report the specific wound-healing observation; I searched for cutaneous wound repair and senescence. (LLM, conf=0.78)
- Partly supportedcites [8] 8. Demaria M, et al. An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA. Dev Cell. 2014; 31:722-733. [PubMed: 25499914] sourceExperimental — accuracy not yet measured
The Results section ('Elimination of Senescent Cells Delays Cutaneous Wound Healing'; page unavailable) reports that senescent cells facilitate cutaneous wound repair. The Experimental Procedures ('Mice'; page unavailable) describe p16-3MR mice treated with GCV, not 18-month-old ATTAC mice treated with AP. Our copy does not report wound repair after AP administration was suspended during healing. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Clearance had no impact on the spectrum or incidence of postmortem tumors, which is consistent with the hypothesis that senescent cells help create a tissue microenvironment that promotes tumor progression 1 .”
What the sources say
- Could not verifycites [1] 1. Campisi J. Aging, cellular senescence, and cancer. Annual review of physiology. 2013; 75:685-705. sourceExperimental — accuracy not yet measured
The Senescent Cells and Cancer section discusses how senescent cells can promote tumor growth, but it does not report whether clearing them changed the spectrum or incidence of postmortem tumors. The Immune Clearance section discusses clearance by immune cells, not postmortem tumor outcomes. Searches for postmortem tumors and tumor incidence after clearance found no passage addressing that result. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
83 more claims
Create a free account to see all 135 claims and every source verdict.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The expression of p16Ink4a is essentially undetectable in young and healthy tissues, but p16Ink4a+ cells accumulate in many aged or diseased tissues.18,19,21,22,23,28”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablating p16+ cells in these mice suppresses age-related disease, extending the health span of two independent strains of transgenic mice: INK-ATTAC and p16-3MR (see Supplemental Figure 1 for a description of the models) (8–10).”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AP20187, a molecule that induces apoptosis in p16INK4a-expressing cells8”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting the notion that senescent cells progressively accumulate in the organism during aging at previously described rates for mice30.”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glomerular endothelial cells140 and proximal tubular epithelial cells (TECs)140,141 become senescent with ageing in mice, showing increased SA-β-gal staining and Cdkn2a expression.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [141]
Experimental — accuracy not yet measured
77 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Statistical analysis
“For consistency in these comparisons, the following denotes significance in all figures: * P < 0.05, ** P < 0.01 and *** P < 0.001.”
§ Extended Data
“Log-rank tests were used to determine statistical significance. *, P<0.01; ** P<0.001; ***, P<0.001.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mouse strains and drug treatments
“Mice from this cohort were randomly assigned to be injected with AP20187 (B/B homodimerizer, Clontech, Mountain View, CA, USA) or vehicle twice a week beginning at 12 months of age.”
§ Mouse strains and drug treatments
“Dosing was 0.2 μg AP20817/g body weight between 12 and 18 months (the same dose as previously used for senescent cell clearance in BubR1 progeroid mice; see reference 4), and 2.0 μg AP20187/g body weight from thereon.”
Citations
Cites
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 8×
“ATTAC MEFs were generated as previously described 4 .”
InfluentialSelf-citationAging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623 · cited 2×
“All studies described using ATTAC mice were performed on transgenic line 3, which contains 13 copies of the transgene inserted into a single locus (data available upon request).”
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363 · cited 1×
“…p16 Ink4a -positive cells is not associated with any overt detrimental effects raise the possibility that this approach may be useful to treat aspects of age-related functional decline, age-related diseases that involve senescent cells, or side-effects of therapies that create senescent cells 36 .”
Self-citationAn Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739 · cited 1×
“Angiotensin receptor blockers attenuate age-related glomerulosclerosis under normotensive conditions, which has led to the idea that overactivation of the local renin-angiotensin-aldosterone system (RAAS) drives the formation of sclerotic glomeruli 31, 32 .”
Programmed cell senescence during mammalian embryonic development
Muñoz-Espín, D., Cañamero, M., Maraver, A., Gómez-López, G., Contreras, J., Murillo-Cuesta, S., Rodríguez-Baeza, A., Varela-Nieto, I., Ruberte, J., Collado, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.019 · Cited by 1,428
Senescence is a developmental mechanism that contributes to embryonic growth and patterning
Storer, M., Mas, A., Robert-Moreno, A., Pecoraro, M., Ortells, M. C., Di Giacomo, V., Yosef, R., Pilpel, N., Krizhanovsky, V., Sharpe, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.041 · Cited by 1,186 · cited 1×
“Furthermore, recent studies showing that senescent cells have beneficial effects in injury repair and tissue remodelling 6–10 have called into question the simplistic view of senescence as only a driver of age-dependent pathologies, raising the specter that senescent cell clearance might remove…”
Forging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104 · cited 1×
“ATTAC was also not induced in peripheral blood T lymphocytes that robustly engage endogenous p16 Ink4a with aging without concomitant expression of multiple senescence markers 2, 13 (Extended Data Fig.”
Research works printed but not linked: 2
- 38. Baker DJ, et al. Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol. 2012; 15:96-102. [PubMed: 23242215] · DOI · Paper page
- 48. Baker DJ, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nature genetics. 2004; 36:744-749. [PubMed: 15208629] · DOI · Paper page
Cited by
Items 2,801–2,883 of 2,883
Directed evolution of compact synthetic promoters via AlphaGenome and genetic algorithmsPreprint
聂麟枭 (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.28.735069
Billard, P. (2021) · theses.fr (ABES) · doi:10.70675/7d145f6az2700z4c8bzad56z3286d493fb31
Triglia, E. T., Miller, T. E., Durand, N. C., Kim, K. L., Casaní-Galdón, S., D’Antonio, J., Javed, N., Hernandez, A. P., Raman, A., Cruz, A. J., et al. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101304
Trastus, L. A., & di Fagagna, F. D. (2026) · Aging · doi:10.18632/aging.206414
“Senescent cell clearance in mice resulted in delayed onset or attenuation of age-related pathologies, including sarcopenia, cataracts, and lipodystrophy, and improved overall healthspan [8 – 11], with a study also reporting an increase in median and maximal lifespan [9].”
Ochiiwa, H., Wakasa, T., Kataoka, Y., Ando, K., Oki, E., Maehara, Y., Iimori, M., & Kitao, H. (2026) · Cancer Science · doi:10.1111/cas.70329 · Cited by 3
Injury and regeneration in renal aging
Bábíčková, J., Yang, H., & Fogo, A. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823318-4.00032-9
Unlocking the dark matter: noncoding RNAs and RNA modifications in cardiac aging
Kang, J., Rhee, J., Wang, C., Yang, Y., Li, G., & Li, H. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00532.2023 · Cited by 1
Aristolochic Acid Nephropathy as a Potential Model of Renal SenescencePreprint
Urate, S., Wakui, H., Azushima, K., Yamaji, T., Suzuki, T., Abe, E., Tanaka, S., Taguchi, S., Tsukamoto, S., Kinguchi, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-620317/v1
Effects of anti-fibrotic standard of care drugs on senescent human lung fibroblastsPreprint
Garcia, S. B., Hohmann, M. S., Coelho, A. L., Verri, W. A., Jr., & Hogaboam, C. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490939
The Assessment of the Older Woman with Breast Cancer
Balducci, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-11875-4_14
AGING WITH T CELLS: The Rise of Regulatory T-cell Features at Older Age
Pieren, D. K. J. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/572
Modulation de la sénescence induite par les oncogènes par les glucocorticoïdes et rôle de EGR1
Carvalho, C. (2018) · theses.fr (ABES) · doi:10.70675/7cafc6a4za30dz467dz81a1z7033a7846a52
SENOLYTICS – A DISCOVERY THAT COULD TRANSFORM THE COURSE OF AGING AND CHRONIC DISEASES
Kania, K., Bobiński, M., Wieczorek, Z., Skowron, W., Bartol, J., Sosińska, A., Rajczyk, J., Wiczuk-Wiczewska, M., Szymczak, A., & Lepich, T. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5128
Matveeva, K. S., & Shevyrev, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188416
Gatto, F., & Ueda, P. (2020) · medRxiv · doi:10.1101/2020.04.27.20081406
Muñoz‐Cánoves, P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734035096.793551787
Integrating senotherapeutics into transplantation: liver reconditioning in an aging donor pool
Buch, M. L., Esser, H., Perera, H., Zheng, R., Ferreira-González, S., & Forbes, S. J. (2026) · Transplant International · doi:10.3389/ti.2026.16347
OKSYDAZY NADPH JAKO ATRAKCYJNY CEL TERAPII PRZECIWNOWOTWOROWEJ
Piszczatowska, K., & Mosieniak, G. (2019) · Kosmos · doi:10.36921/kos.2019_2500
Kim, J. Y., Atanassov, I., Dethloff, F., Kroczek, L., & Langer, T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.13.512077
Systemic Risk in Post-Crisis Financial Markets
(2019) · University of Finance and Administration eBooks · doi:10.37355/03.2019/2 · Cited by 1
Oyabu, M., & Kamei, Y. (2025) · KAGAKU TO SEIBUTSU · doi:10.1271/kagakutoseibutsu.63.123
The senescence–immune axis as a target for combining immunotherapy and senotherapy
Saez‐Calazans, F., Grün, L. K., Stein, L. E., Barbé‐Tuana, F. M., & Filippi‐Chiela, E. C. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103309
The Effects of Early-Life Drug and Dietary Interventions on Late-Life Disease Development
Mau, T. (2019) · Deep Blue (University of Michigan)
Plasma Cells: Antibody and Beyond
Cuc, B. T., Manfroi, B., Tong, Y., Nguyen, T. N., Behi, M. E., & Fillatreau, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00064-8
大石, 由., & 真鍋一郎 (2018) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.52.1_5
Cellular Senescence and Tumor Promotion
Demaria, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-44870-1_79-1
Pukhalskaia, T. V., Yrakova, T. R., Bogdanova, D. A., & Demidov, O. N. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524050058
Oh, J. H., Ku, C. R., & Oh, C. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103349
Wu, W. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240628ww
Vardon, A., Haston, S., Guiho, R., Carvahlo, D., Carter, R., Boult, J. K. R., Gharai, D., Santhakumar, D., Cloete, I., Gray, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629607 · Cited by 1
A biological perspective of ageing
Guerville, F., & Lemoine, M. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch1
Senescent cell heterogeneity in brain aging and neurodegenerative disease
Graves, S. I., Vasques, P. D. C., & Baker, D. J. (2026) · Neuron · doi:10.1016/j.neuron.2026.06.020
Self-citationSoysouvanh, F. (2019) · theses.fr (ABES) · doi:10.70675/3890835fzb557z430aza571z697de58045dd · Cited by 1
Mourkioti, I., Polyzou, A., Veroutis, D., Theocharous, G., Lаgopati, N., Gentile, E., Stravokefalou, V., Thanos, D.-F., Havaki, S., Kletsas, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803087
Luo, R., Chen, Q., Wang, J., Nie, Z., Dan, L., & Xie, S. (2026) · Biomedicines · doi:10.3390/biomedicines14081869
Mapping the research trends and hotspots in vascular aging from 2003–2023: A bibliometric analysis
Ji, Z., Chen, S., Cheng, J., Qiu, Y., Wang, X., Wang, J., Sun, Y., Li, B., & Zhou, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38571 · Cited by 1
“Strong preclinical data show that depletion of p16 expressing senescent cells can significantly extend lifespan and health span in mouse models [72].”
BackgroundTizard, I. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-29178-4.00026-5
Reversing Immunosenescence with Senolytics to Enhance Tumor ImmunotherapyPreprint
Liu, N., Wu, J., Deng, E., Zhong, J., Wei, B. K., Cai, T., Duan, X., Fu, S., Osei-Hwedieh, D. O., Sha, O., et al. (2024) · medRxiv · doi:10.1101/2024.10.14.24315428
Self-citationINNOVATIVE APPROACHES TO COMBAT SKIN AGING: ADVANCES IN WRINKLE AND SAGGING TREATMENTS
NIKAM, K. D., ELANGO, V., VENTRIAL, K., M., Y., & Murugappan, M. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.52837 · Cited by 1
Anti-aging Concepts: Adipose Tissue as a Therapeutic Target in Anti-aging Medicine
Knoedler, S., & Prantl, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-01711-6_17
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741984
Mourkioti, I., Polyzou, A., Veroutis, D., Theocharous, G., Lagopati, N., Gentile, E., Stravokefalou, V., Thanos, D.-F., Havaki, S., Kletsas, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23803084
Additional file 3 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749316
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617409
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26157578
Additional file 1 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26308954
Liu, F., Wan, Q., Liu, P., 苗登顺, Dai, X., & Chen, L. (2024) · Figshare · doi:10.6084/m9.figshare.26573578
Additional file 5 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749322
Additional file 2 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26309093
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617418
Additional file 4 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749319
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617421
Sanada, Y., Ikuta, Y., Ding, C., Shinohara, M., Yimiti, D., Ishitobi, H., Nagira, K., Lee, M., Akimoto, T., Shibata, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21358127
Additional file 9 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749334
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741990
Additional file 7 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749328
Garana, B. B., Joly, J. H., Delfarah, A., Hong, H., & Graham, N. A. (2024) · Figshare · doi:10.6084/m9.figshare.26591531
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617424
Wu, Z., Uhl, B., Gires, O., & Reichel, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.26578268
Sasaki, N., Itakura, Y., & Toyoda, M. (2020) · Figshare · doi:10.6084/m9.figshare.11978682
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617433
Additional file 8 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749331
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741987
Additional file 1 of Decreased thymic output predicts progression of chronic kidney disease
Iio, K., Kabata, D., Iio, R., Shibamoto, S., Watanabe, Y., Morita, M., Imai, Y., Hatanaka, M., Omori, H., & Isaka, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26568466
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741981
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617427
Lujan, C., Tyler, E. J., Ecker, S., Webster, A. P., Stead, E. R., Martinez-Miguel, V. E., Milligan, D., Garbe, J. C., Stampfer, M. R., Beck, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26157203
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617412
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617436
Wang, X., Cai, Y., Wu, C., Liang, J., Tang, K., Lin, Z., Chen, L., Lu, Y., & Wang, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23902906
Gong, X., Shen, H., Guo, L., Huang, C., Su, T., Wang, H., Feng, S., Yang, S., Huo, F., Liu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617430
Additional file 6 of Endometrial senescence is mediated by interleukin 17 receptor B signaling
Kawamura, K., Matsumura, Y., Kawamura, T., Araki, H., Hamada, N., Kuramoto, K., Yagi, H., Onoyama, I., Asanoma, K., & Kato, K. (2024) · Figshare · doi:10.6084/m9.figshare.26749325
Li, K., Li, Y., Yu, Y., Ding, J., Huang, H., Chu, C., Hu, L., Yu, Y., Cao, Y., Xu, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14173917
Stem Cell Secretome for Aging Therapy: Potential Benefits and Key Challenges
Chen, M., & Xing, L. (2026) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x436321251206110646 · Cited by 1
Les cellules sénecentes comme niche de survie : rôle de la voie TSP1-CD47
Moreau, M. (2017) · theses.fr (ABES) · doi:10.70675/e62d69b6z1f00z4f88z817bzda54e624150f
Simpson, D. J., Crofts, S., Mavrommatis, C., White, T. A., Suwanlikit, Y., Loyva, K., Rocca, W. A., Kantarci, K., Mielke, M. M., Richmond, A., et al. (2026) · medRxiv · doi:10.64898/2026.09.29.26364335
The Effect of Chronic Inflammation on Cellular Aging Processes and Current Treatment Approaches
Başaran, A. (2026) · Uluslararası Sağlık Bilimlerinde Disiplinler Arası Etkileşim Dergisi · doi:10.65349/nxpt1964
Zhang, L. J., Salekeen, R., Soto-Palma, C., Wu, Q., He, Y., Elsallabi, O., Bdiri, B., Hughes, B., Nunes, A., Xu, W., et al. (2026) · Aging Cell · doi:10.1111/acel.70736
“Studies using transgenic mouse models, where p16 Ink4a or p21 Cip1 - positive senescent cells can be selectively ablated, have demonstrated the pivotal role of senescent cells in driving aging and age-related diseases (Baker et al. 2016, 2011; Wang et al. 2021).”
Wang, J., Yang, M., Li, Y., Wan, Y., Zhan, X., & Liang, H. (2026) · Frontiers in Nephrology · doi:10.3389/fneph.2026.1905354
Huang, J., Ji, L., Jin, H., Shi, Z., Song, X., Cai, Y., & Tong, X. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103398
Small extracellular vesicles as mediators of paracrine senescence in cellular models of aging
Llabrés-Mas, A. M., Merino-Navarro, A., Menendez-Garcia, M., & O’Loghlen, A. (2026) · Aging · doi:10.18632/aging.206425
Metadata
- Authors
- Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., Khazaie, K., Miller, J. D., & van Deursen, J. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Baker, Darren J.
- van Deursen, Jan M.
- ORCID
- Venue
- Nature
- Published
- 2016-02
- Volume
- 530
- Issue
- 7589
- Pages
- 184-189
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4845101
- OpenAlex
- W2266290735
- Cited by
- 2,876
- References
- 50
- Citations by year
- 2026: 254 · 2025: 253 · 2024: 318 · 2023: 298 · 2022: 305 · 2021: 286 · 2020: 312 · 2019: 279 · 2018: 236 · 2017: 210 · 2016: 123
- FWCI
- 116.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute on Aging (P01AG041122, R37AG013925)
- National Heart, Lung, and Blood Institute (R01HL111121)
- National Cancer Institute (R01CA166347, R01CA096985, P30CA015083)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- cellular senescence, p16INK4a, senolytics, healthspan, aging, senescent cell clearance, carcinogenesis, renal function, cardiac KATP channels, adipocytes, AP20187, CDKN2A
- MeSH terms
- Aging, Animals, Cell Separation, Cell Transformation, Neoplastic, Epithelial Cells, Female, Health, Kidney, Lipodystrophy, Longevity, Male, Myocardium, Organ Specificity, Stem Cells, Time Factors, Cellular Senescence, Apoptosis, Adipocytes, Cyclin-Dependent Kinase Inhibitor p16, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.